Twitter Beğeni Hilesi

🚨 NEWS 🚨 U.S. FDA grants fast track designation to CB-012, an allogeneic anti-CLL-1 CAR T-cell therapy, for the treatment of patients with relapsed/refractory AML. Read more: loom.ly/zm6V7s8 #AMLsm #leusm #MedNews

CONGRESS | #SOHO2024 Eunice Wang Roswell Park provides an update on menin inhibitors for the treatment of #AML. Wang shares the latest clinical trial data for investigational menin inhibitors; noting the clear clinical activity but short duration of response, driving further

CONGRESS | #SOHO2024 Mark Levis Johns Hopkins Medicine discusses the unanswered question in FLT3 Mutated AM; emphasizing the importance of sequencing in individualized treatment strategies and the need for further investigation of multiclonal FLT3-ITD. #AMLsm #leusm

CONGRESS | #SOHO2024 Chris Hourigan Fralin Biomedical Research Institute discusses MRD as a surrogate endpoint for clinical trials in #AML, emphasizing the difference between the cases for regulatory and clinical use but noting that there is potential for its use as a surrogate in the future. #AMLsm

CONGRESS | #SOHO2024 Keith Pratz Keith W Pratz MD Penn Medicine debates the case that azacytidine plus venetoclax should be prescribed as listed on the label; concluding that the data from the VIALE-A trial is the only randomized data set demonstrating a survival benefit, therefore until

CONGRESS | #SOHO2024 Stéphane De Botton, Gustave Roussy, debates the case that AZA + VEN dose reductions are not detrimental, and that shorter VEN durations, as recommended by the ELN, may allow hematological recovery. He also cites a French study showing no significant

Cristina Papayannidis, Universitaria di Bologna, Bologna, IT, shares how she treats a patient with DNMT3A-mutated AML in remission post intensive chemotherapy. Watch the full video here: loom.ly/b0D830o #AMLsm #leusm #MedEd

CONGRESS | #SOHO2024 Jayalekshmi Jayakumar, The Brooklyn Hospital Center, shares findings from a nationwide study evaluating the role of aspirin in improving leukemia outcomes. Out of 1,663,149 leukemia-related hospitalizations, 11.2% were aspirin users, who were older than non-users, and

CONGRESS | #SOHO2024 Dr. Eduardo Rego, USP - Universidade de São Paulo, discusses the international expansion of modern AML therapies, highlighting the need for better molecular testing and access to novel treatments in low- and middle-income countries. To address these gaps, the ICAML2015 protocol was

CONGRESS | #SOHO2024 Charles Craddock, The Queen Elizabeth Hospital, discusses identification of patients with AML over 70 years in CR1 who could benefit from transplant, optimal conditioning regimen, and post-transplant maintenance strategies to minimize the risk of relapse. Suitability for

CONGRESS | #SOHO2024 | Poster Priti Pednekar presents an observational study assessing adherence and persistence to FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML (N=162). Patients with pre-alloHCT R/R AML were more likely to be adherent (41.5% vs 21.4%,

CONGRESS | #SOHO2024 | Poster Harry Erba, Duke Cancer, presents a post hoc analysis of QuANTUM-First study assessing the impact of age on efficacy of quizartinib in patients with ND FLT3-ITD+ AML. Among 297 pts achieving CR at the end of induction, CR rates were similar with

CONGRESS | #SOHO2024 | Poster Uma Borate, The James, presents phase II SELECT-AML-1 (NCT04905407) results of tamibarotene + Ven/Aza in pts with ND unfit AML with RARA overexpression (N=51). CR/CRi rates were 60% with tamibarotene/Ven/Aza vs 69% with Ven/Aza. The combination

CONGRESS | #SOHO2024 | Poster Manuel Espinoza-Gutarra, UAB O'Neal Comprehensive Cancer Center, presents real-world outcomes of FLT3- or IDH-targeted TKI therapy in pts with AML (N=482). Patients treated at first line vs second line or beyond had similar rwEFS (2.2 vs 2.5 months) and rwOS (12.3 vs 13.1

CONGRESS | #SOHO2024 | Poster Samer Srour, MD Anderson Cancer Center, presents subgroup analysis of phase Ib (NCT04013685) trial of Orca-T in patients with AML (N=37). At 12 months, relapse-free survival was 82.5%, non-relapse mortality was 0%, and overall survival was 100%. #AMLsm #leusm

CONGRESS | #SOHO2024 | Poster Alexander Perl, Penn, presents potential prognostic utility of FLT3-ITD-specific MRD assessment in pts with AML from the phase III QuANTUM-First trial (n=321 with available MRD data). Reduction in FLT3-ITD MRD was associated with longer OS across

CONGRESS | #SOHO2024 | Poster Jorge Cortes, Augusta University, presents 5-year data from phase II registration trial (NCT02719574) of olutasidenib in a subgroup of pts with AML following venetoclax failure (N=18). In 16 pts with IDH1m AML R/R to venetoclax, CR/CRh rate was 31%,